Novartis Enters Licensing Agreement with Abogen for RNA Therapeutics
Novartis has entered into a licensing and option agreement with China-based Abogen Biosciences to develop RNA-encoded therapeutics. Under the deal, Abogen will receive an upfront payment of $575 million from Novartis. The total potential value of the collaboration could reach up to $7.8 billion if all options on all programs are exercised. The partnership highlights growing interest in RNA-based therapies and strengthens Novartis's pipeline for innovative treatments, while providing Abogen with significant financial support and global development capabilities through a major pharmaceutical partner. This deal reflects the increasing strategic importance of RNA technology in drug discovery and could influence investor sentiment toward both companies.
Tickers: $NVS